---
layout: default
title: Raloxifene
parent: Model Prediction Only (L5)
nav_order: 1105
evidence_level: L5
indication_count: 4
---

# Raloxifene
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **4** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Raloxifene: From Its Marketed Use (Not Recorded in the Data) to Duodenal Ulcer

## One-Sentence Summary

Raloxifene is a marketed oral tablet in the United States, but the input data does not record its approved indication.
The TxGNN model predicts it may be effective for **duodenal ulcer**, but **0 clinical trials** and **0 publications** currently support this direction, so the prediction rests on the model alone.

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Duodenal ulcer |
| TxGNN Prediction Score | 99.72% (model rank 75) |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the five listed below are ANDA generics) |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available, and the original indication was not captured in the input. Raloxifene is generally known as a selective estrogen receptor modulator (SERM). This is background knowledge, not something verified in the Evidence Pack.

A possible link is that estrogen-receptor modulation could influence gastric or duodenal mucosal defense. This is speculative. No trial, publication or mechanistic data supports it, and the high score (0.997) may reflect proximity to related gastrointestinal nodes in the knowledge graph rather than a drug-specific effect.

The same model run also ranked hypoalphalipoproteinemia (99.65%), duodenal obstruction (99.64%) and duodenogastric reflux (99.59%) as further candidates. All are L5 with no supporting studies and are also on Hold. Duodenal obstruction is typically a structural condition, so a drug indication for it is unlikely.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## US Market Information

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|------|
| ANDA090842 | Raloxifene Hydrochloride | Tablet | Cipla USA Inc. |
| ANDA211324 | Raloxifene hydrochloride | Tablet, coated | Cadila Pharmaceuticals Limited |
| ANDA208206 | Raloxifene Hydrochloride | Tablet, film coated | AvPAK |
| ANDA204310 | Raloxifene Hydrochloride | Tablet, film coated | Aurobindo Pharma Limited |
| ANDA206384 | Raloxifene hydrochloride | Tablet, film coated | Bryant Ranch Prepack |

All listed products are oral. Approved indication text was not available in the input.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The only support is a knowledge-graph score, with no clinical trials, no literature and no verified mechanism. Approved-indication and safety data are also missing, so the candidate cannot move past initial screening.

**To proceed, the following is needed:**
- Package insert warnings, contraindications and approved indications (from the FDA label)
- Mechanism of action data (for example, from DrugBank)
- A targeted search of ClinicalTrials.gov and PubMed for raloxifene in duodenal ulcer, to check whether any real evidence exists
- A mechanistic rationale showing how SERM activity could plausibly affect duodenal mucosa, before any further investment

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

